|
Resolution: standard / high Figure 1.
Sub-cellular localization of incoming HIV-1 in quiescent CD4+ T cells. A. Incoming HIV-1 CA localizes at the centrosome in infected human primary quiescent
CD4+ T cells. Quiescent CD4+ T cells (0.5 × 106 cells) were spinoculated with the NL4.3 strain of HIV-1 (moi = 1) as described [34].
The NL4.3 viral stock was obtained from 24-h harvests of supernatant from 293T cells
transduced with a plasmid encoding the full-length viral genome and was titrated by
limiting dilution MAGI assay [35]. At the indicated time points, infected and control
cells were fixed in 4% PFA (15 min, 4°C), permeabilized with ice-cold methanol (5
min, 4°C) and stained with antibodies against HIV-1 CA protein (A25, Hybridolabs,
Pasteur) and γ-tubulin (Abcam), a marker for the centrosome. Nuclei were stained with
DAPI and images were acquired on a laser-scanning confocal microscope (LSM510 Meta;
Carl Zeiss) equipped with an Axiovert 200 M inverted microscope, using a Plan Apo
63/1.4-N oil immersion objective. Co-localization between CA and γ-tubulin staining
was observed in 58% to 75% of CA-positive cells. B) HIV-1 infection did not significantly alter the activation status of quiescent CD4+
T cells. Surface expression of T cell activation markers (CD25 and HLA-DR) was monitored
by flow cytometry. C) Pericentriolar distribution of incoming HIV-1 CA in quiescent CD4+ T cells transduced
with a VSVg-pseudotyped HIV-1 based lentivector carrying the GFP transgene. The lentivector
stock was produced by co-transfected with an HIV-derived packaging construct, the
VSVg-expressor vector and the plasmid vector (psPAX2, pMD2.G and pWPI, respectively,
a gift from D. Trono), as described [35]. The titre of the lentivector stocks was
determined by measuring the percentage of GFP positive cells 48 h following transduction
of 293T cells by flow cytometry. Transduced and control quiescent CD4+ T cells were
immunostained and visualized as described above. Co-localization between CA and γ-tubulin
staining was observed in 60% to 82% of CA-positive cells.
Zamborlini et al. Retrovirology 2007 4:63 doi:10.1186/1742-4690-4-63 |